Poland Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Poland pharmaceutical market size was $10.0 billion in 2021. The market grew at a CAGR of more than 5% during 2013-2019.  The growth of Poland’s pharmaceutical industry is attributed to its universal health coverage, advanced and government-supported infrastructure, increased foreign business investments, enhanced regulatory compliance, and well-developed logistics and clinical trials market.

Poland Pharmaceutical Market, Outlook

Poland Pharmaceutical Market, Outlook

For more pharmaceutical insights in Poland healthcare market, download a free report sample

Poland medical devices market size was $4.8 billion in 2021. The market is expected to grow at a CAGR of more than 5% during the period 2022-2027. In 2020, Poland has demonstrated the most innovative and promising medical technology solutions.

The Poland Healthcare (Pharma and Medical Devices) market research report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Poland. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets.

Poland Medical Devices Market, Outlook

Poland Medical Devices Market, Outlook

For more medical devices insights in Poland healthcare market, download a free report sample

Market Dynamics in the Poland Pharmaceutical Market

  • The drug distribution system in Poland comprises wholesalers, pharmaceutical outlets, pharmacies, and online pharmacies.
  • Pharmaceutical manufacturing and distribution are privatized in Poland.
  • Community pharmacies conduct retail distribution of prescription drugs. OTC drugs can be purchased through open pharmacies, other pharmacies, supermarkets, tobacco shops, and newspaper stands, as decided by the MOH.
  • Online pharmacies that follow guidelines laid out under the Pharmaceutical Law of 2001 can also disperse OTC drugs.
  • In February 2019, the Polish pharmaceutical industry, community and hospital pharmacies, wholesalers, and parallel traders were obliged to comply with the EU-wide Falsified Medicines Directive (FMD) legislation (2011/62/EU) to ensure proper tracking and authentication of dispensed medicinal products.

Key Segments in the Poland Pharmaceutical Market

The key segments in the Poland pharmaceutical market are generics, biologics, biosimilars, and over-the-counter (OTC).

Key Players in the Poland Pharmaceutical Market

The key players in the Poland pharmaceutical market are Sanofi, Bayer AG (Bayer), Novartis, GlaxoSmithKline, F. Hoffmann-La Roche Ltd. (Roche), and Bioton.

Sanofi

Sanofi is a healthcare company that researches, develops, manufactures, and markets a wide range of medicines and vaccines. It has operations across Europe, the Americas, Asia-Pacific, Africa, and the Middle East. Sanofi is headquartered in Paris, France. Sanofi’s Poland offices are located in Warsaw.

Novartis

Novartis is a healthcare company that focuses on the discovery, development, manufacture, and marketing of prescription and generic pharmaceutical products, as well as eye care products. It provides drugs for the treatment of cancer and other diseases. Novartis’ headquarters is in Basel, Switzerland. Its Poland offices are located in Warsaw and Pruszkow.

GlaxoSmithKline (GSK)

GlaxoSmithKline (GSK) is a healthcare company that focuses on the development, manufacture, and commercialization of pharmaceuticals, vaccines, and consumer healthcare products. It offers drugs for the treatment of respiratory diseases, cancer, cardiovascular diseases, human immunodeficiency virus (HIV), infectious diseases, immuno-inflammation, and rare diseases. Its headquarters is in Brentford, London. Its Polish offices are located in Poznan.

Hoffmann-La Roche Ltd. (Roche)

Hoffmann-La Roche Ltd. (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases including auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in-vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche’s headquarters is in Basel, Switzerland. Its Polish offices are located in Warsaw.

Bioton

Bioton is a biotechnology company that manufactures medicines, pharmaceutical preparations and produces pharmaceutical substances with a focus on diabetes care.  The company provides strips for monitoring of blood sugar and over-the-counter (OTC) preparations including diet supplements, with certain health problems such as metabolic syndrome and diabetes. The company operates in Europe, Asia, and Australia. Bioton’s headquarters are in Ozarow Mazowiecki, Masovian, Poland.

Key Segments in the Poland Medical Devices Market

The key segments in the Poland medical devices market are cardiovascular devices, hospital supplies, general surgery, orthopedic devices, diabetes care devices, and others.

Key Players in the Poland Medical Devices Market

The key players in the Poland medical devices market are Fresenius SE & Co. KGaA (Fresenius), Medtronic, Abbott, Stryker Corp (Stryker), and MedicALgorithmics

Fresenius SE & Co. KGaA (Fresenius)

Fresenius SE & Co. KGaA (Fresenius) is a global healthcare group that offers products and services for dialysis, hospitals, and outpatient treatment. It has major manufacturing plants in the US, Germany, China, Sweden, and Japan. The company is headquartered in Bad Homburg, Hessen, Germany, with its Poland office located in Warsaw.

Medtronic

Medtronic is a medical technology company that designs, develops, manufactures, and markets a wide range of medical devices and solutions for the treatment of heart valve disorders, heart failure, coronary artery diseases, aortic, peripheral vascular, venous renal and neurological diseases, spine and musculoskeletal disorders and ENT diseases. Medtronic is headquartered in Dublin, Ireland, with its Poland office located in Warsaw.

Abbott

Abbott is a diversified health product company that manufactures and markets drugs, diagnostics, branded generics, vascular products, and nutritional products. The company’s products comprise specialized medicines, medical diagnostic instruments and tests, minimally invasive surgical devices, and products for veterinary care. Abbott is headquartered in Illinois, US, with its Poland office located in Warsaw.

Stryker Corp (Stryker)

Stryker Corp (Stryker) is a medical technology company that manufactures an array of orthopedic, medical and surgical, and neurotechnology and spine products and allied services. The company offers products to doctors, hospitals, and other healthcare facilities. Stryker is headquartered in Kalamazoo, Michigan, US, with its Poland office located in Warsaw.

MedicALgorithmics

MedicALgorithmics is a medical device company that designs, develops, and markets cardiac monitoring devices. The company manufactures Pocket ECG, a non-invasive mobile ECG, and arrhythmia diagnostic technology. It partners with hardware, software, programming, and IT infrastructure companies. MedicALgorithmics is headquartered in Warsaw, Poland.

Market report overview of pharmaceutical market in Poland

Market size 2021 $10.0 billion
CAGR % (2013-2019) >5%
Key segments Generics, Biologics, Biosimilars, and Over-The-Counter (OTC)
Major players Sanofi, Bayer AG (Bayer), Novartis, GlaxoSmithKline, F. Hoffmann-La Roche Ltd. (Roche), and Bioton

Market report overview of medical devices market in Poland

Market size 2021 $4.8 billion
CAGR% (2022-2027) >5%
Key segments Cardiovascular Devices, Hospital Supplies, Orthopedic Devices, General Surgery, Diabetes Care Devices, and Others.
Major players Fresenius SE & Co. KGaA (Fresenius), Medtronic, Abbott, Stryker Corp (Stryker), and MedicALgorithmics

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Poland, and includes:

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers.
  • Profiles and SWOT analyses of the major players in the pharmaceutical market: Bioton, Sanofi, Novartis, GSK, and Roche.
  • Profiles and SWOT analyses of the major players in the medical device market: Fresenius, Medtronic, Abbott, Stryker, and MedicALgorithmics.
  • An insightful review of the COVID-19 epidemiology, COVID-19 impact and developments in healthcare market, HealthTech landscape, reimbursement and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices.
  • Detailed analysis of the country’s healthcare policy highlights, demographics, healthcare infrastructure and healthcare expenditure.
  • An overview of the opportunities for and challenges to growth in the Poland healthcare market.

Reasons to Buy

This report will enhance your decision-making capability by allowing you to:

  • Develop business strategies by understanding the trends shaping and driving Poland healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact Poland healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership

Table of Contents

1. Table of Contents

1.1 List of Figures

1.2 List of Tables

2. Executive Summary

2.1 Executive Summary

2.2 Key Highlights – Facts about the Poland Healthcare Market

2.3 Key Highlights: Healthcare Startups in Poland

2.4 Key Events: Poland Healthcare Timeline, 2016–22

2.5 Key Events: Poland Pharmaceutical Market

2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2020–22

2.7 Key Events: Mergers and Acquisitions

2.8 Country Profile, Poland, 2021

3. Overview of Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Exports

3.3 Pharmaceutical Market – Imports

3.4 Pharmaceutical Market – Supply Channels, Poland

3.5 Pharmaceutical Market – Market Segments

3.6 Pharmaceutical Market – Market Segments, Generics, Poland

3.7 Pharmaceutical Market – Market Segments, Biologics and Biosimilars, Poland

3.8 Pharmaceutical Market – Market Segments, Over-the-Counter Medicines, Poland

3.9 COVID-19 Epidemiology, Poland

3.10 COVID-19 Impact and Developments in the Healthcare Market, Poland

3.11 COVID-19 Clinical Trials Landscape, Poland

3.12 Pharmaceutical Market – Major Players

4. Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Device Market – Major Segments

4.3 Medical Device Market – Hospital Supplies Market

4.4 Medical Device Market – Cardiovascular Devices Market

4.5 Medical Device Market – General Surgery Market

4.6 Medical Device Market – Orthopedic Devices Market

4.7 Medical Device Market – Diabetes Care Devices Market

4.8 Medical Devices Market – Diagnostics Market

4.9 Medical Devices Market – Major Players

5. Pharmaceutical and Medical Devices Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6. Deal Analysis

6.1 Deal Analysis: Pharmaceutical Market, Poland, 2019–22

6.2 Deal Analysis: Medical Device Market, Poland, 2019–22

7. HealthTech Landscape

7.1 HealthTech Landscape, Poland

7.2 HealthTech Deals Landscape, Poland

7.3 Key HealthTech Deals, Poland

7.4 Adoption of Technology in Healthcare, Poland

7.5 Regulatory Scenario Covering Use of Technology in Healthcare, Poland

7.6 HealthTech Landscape: Benefits and Risks, Poland

8. Market Access

8.1 Overview of Healthcare System, Poland

8.2 Reimbursement Process, Poland

8.3 Overview of Insurance Providers, Poland

8.4 Healthcare Spending and Prescription Drug Price Trend, Poland

8.5 Pricing Policies, Poland

8.6 Market Access: Key Events Timeline, Poland, 2010–21

8.7 Regulatory Landscape, Poland

8.7.1 Marketing Authorization for Pharmaceutical Products, Poland

8.7.2 Marketing Authorization for Pharmaceutical Products (Centralized Procedure), Poland

8.7.3 Marketing Authorization for Pharmaceutical Products (Decentralized Procedure), Poland

8.7.4 Marketing Authorization for Pharmaceutical Products (Mutual Recognition Procedure), Poland

8.7.5 Marketing Authorization for Medical Devices, Poland

8.7.6 Intellectual Property Rights, Patent, Poland

8.7.7 Intellectual Property Rights, Trademark, Poland

8.7.8 Clinical Trial Regulation Process, Poland

8.7.9 Pharmaceutical Clinical Trials Landscape, Poland

8.7.10 Medical Device Clinical Trials Landscape, Poland

8.7.11 Pharmaceutical Manufacturing and Licensing, Poland

8.7.12 Pharmaceutical Export and Import, Poland

8.7.13 Pharmaceutical Advertising Regulations, Poland

8.7.14 Pharmacy Regulations, Poland

8.7.15 Labeling and Packaging Regulations, Poland

9. Country Healthcare Landscape

9.1 Healthcare Policy Highlights, Poland

9.2 Healthcare Facilities, Poland

9.3 Healthcare Parameters, Poland

9.4 Life Expectancy and Immunization Rate, Poland

9.5 Environmental Health, Poland

9.6 Healthcare Personnel, Poland

9.7 Disease Burden, Poland

9.8 Healthcare Expenditure, Poland

10 Trade Associations, Poland

11 Trade Fairs, Poland

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.2 Bibliography

13.3 About GlobalData

13.4 Contact Us

13.5 Disclaimer

Table

Table 1: COVID-19 indicators (number of cases), Global and Poland, 2022

Table 2: COVID-19-related travel restrictions, Poland, 2020–22

Table 3: COVID-19 IVD Products, Poland, 2021–22

Table 4: COVID-19 vaccines trials, Poland, 2022

Table 5: COVID-19 approved vaccines, Poland, 2022

Table 6: Medical devices market, major segments ($M), Poland, 2021

Table 7: Hospital supplies market, Poland, revenue ($M) and market share (%) of major companies, 2021

Table 8: Cardiovascular devices market, Poland, revenue ($M) and market share (%) of major companies, 2021

Table 9: General surgery market, Poland, revenue ($M) and market share (%) of major companies, 2021

Table 10: Orthopedic devices market, Poland, revenue ($M) and market share (%) of major companies, 2021

Table 11: Diabetes care devices market, Poland, revenue ($M) and market share (%) of major companies, 2021

Table 12: Calculation of product cost, Poland, 2022

Table 13: Fees for filing of patent and protection, Poland, 2022

Table 14: Trade fairs, Poland, 2022

Figures

Figure 1: Pharmaceutical market, revenue ($B), Poland, 2013–21

Figure 2: Medical devices market, revenue ($B), Poland 2016–2021

Figure 3: Healthcare start-ups in Poland, 2022

Figure 4: Country profile, Poland, 2021

Figure 5: Pharmaceutical market, revenue ($B), Poland, 2013–21

Figure 6: Pharmaceutical market, revenue forecast ($B), Poland, 2022–26

Figure 7: Pharmaceutical exports ($B), Poland, 2014–21

Figure 8: Top export partners, Poland, 2021

Figure 9: Pharmaceutical imports ($B), Poland, 2014–21

Figure 10: Top import partners, Poland, 2021

Figure 11: Major generic drug companies, Poland, 2021

Figure 12: OTC medicines market, major distribution channels ($M), Poland, 2021

Figure 13: OTC medicines market, revenue ($B), Poland, 2014–21

Figure 14: OTC medicines market, major categories ($M), Poland, 2021

Figure 15: COVID-19 cases, Poland, 2020–22

Figure 16: COVID-19 deaths, Poland, 2020–22

Figure 17: COVID-19 stringency index (based on vaccination ratio), Poland, 2020–22

Figure 18: COVID-19 containment and health index, Poland, 2020–22

Figure 19: COVID-19 fiscal stimulus timeline, Poland, 2020–22

Figure 20: COVID-19 vaccine doses administration, number of vaccine doses administered, Poland, 2022

Figure 21: Stages of COVID-19 national vaccination program, Poland, 2021

Figure 22: COVID-19 vaccine booster doses administration, number of vaccine doses administered per 100 people, Poland, 2021–22

Figure 23: COVID-19 clinical trials count by trial status, Poland, 2021–22

Figure 24: COVID-19 clinical trials count by market category, Poland, 2021–22

Figure 25: Top COVID-19 clinical trials sponsors by trial count, Poland, 2021–22

Figure 26: Medical devices market, revenue ($B), Poland 2016–21

Figure 27: Medical devices market, revenue forecast ($B), Poland, 2022–27

Figure 28: Medical devices market, major segments (%), Poland, 2021

Figure 29: Hospital supplies market, revenue ($B), Poland, 2018–27

Figure 30: Hospital supplies market, Poland, market share of major players (%), 2021

Figure 31: Cardiovascular devices market, revenue ($M), Poland, 2018–27

Figure 32: Cardiovascular devices market, Poland, market share of major players (%), 2021

Figure 33: General surgery market, revenue ($M), Poland, 2018–27

Figure 34: General surgery market, Poland, market share of major players (%), 2021

Figure 35: Orthopedic devices market, revenue ($M), Poland, 2018–27

Figure 36: Orthopedic devices market, Poland, market share of major players (%), 2021

Figure 37: Diabetes care devices market, revenue ($M), Poland, 2018–27

Figure 38: Diabetes care devices market, Poland, market share of major players (%), 2021

Figure 39: Diagnostics market, revenue ($M), Poland, 2017–21

Figure 40: Diagnostics market, revenue forecast ($M), Poland, 2022–27

Figure 41: Medical devices market, revenue ($B) of major companies, Poland, 2021

Figure 42: Deal value and deal count, pharmaceutical market, Poland, 2019–22

Figure 43: Deal value and deal count subtypes, pharmaceutical market, Poland, 2019–22

Figure 44: Deal value and deal count, quarterly, pharmaceutical market, Poland, 2019–22

Figure 45: Top therapy areas by deal value ($M), pharmaceutical market, Poland, 2019–22

Figure 46: Top therapy areas by deal count, pharmaceutical market, Poland, 2019–22

Figure 47: M&A deals by quarter, pharmaceutical market, Poland, 2019–22 (by value and by number)

Figure 48: Deal value and deal count, medical devices market, Poland, 2019–22

Figure 49: Deal value and deal count subtypes, medical devices market, Poland, 2019–22

Figure 50: Deal value and deal count, quarterly, medical devices market, Poland, 2019–22

Figure 51: Top equipment sectors by deal value ($M), medical devices market, Poland, 2019–22

Figure 52: Top equipment sectors by deal count, medical devices market, Poland, 2019–22

Figure 53: M&A deals by quarter, medical devices market, Poland, 2019–22 (by value and by number)

Figure 54: PE deals by quarter, medical devices market, Poland, 2019–22 (by value and by number)

Figure 55: Deal value ($M) and deal count, Healthtech, Poland, 2020–22

Figure 56: Deal value ($M) based on technology themes, Healthtech, Poland, 2020–22

Figure 57: Four pillars of digital competence development program (2020–30), Poland

Figure 58: Objectives of Polish National AI Strategy, 2019–27, Poland

Figure 59: Digital Health Funding, 2021, Poland

Figure 60: Objectives of the cybersecurity strategy 2019–24, Poland

Figure 61: Organization of healthcare system, Poland, 2022

Figure 62: Public health Insurance Coverage (% of Total Population), Poland, 2012–20

Figure 63: OOP Expenditure (% of Health Spending), Poland, 2012–20

Figure 64: Health price index, Poland, 2012–21

Figure 65:

Figure 65: Centralized Procedure, Poland, 2022

Figure 66: Decentralized Procedure, Poland, 2022

Figure 67: Mutual Recognition Procedure, Poland, 2022

Figure 68: Conformity Assessment of Class I Medical Devices, EU, 2022

Figure 69: Conformity Assessment of Class IIa Medical Devices, EU, 2022

Figure 70: Conformity Assessment of Class IIb Medical Devices, EU, 2022

Figure 71: Conformity Assessment of Class III Medical Devices, EU, 2022

Figure 72: Patent approval process, Poland, 2022

Figure 73: European patent approval process, EU, 2022

Figure 74: Unitary patent approval process, EU, 2022

Figure 75: Trademark approval process, Poland, 2022

Figure 76: Pharmaceutical clinical trials count by trial status, Poland, 2020–22

Figure 77: Pharmaceutical clinical trials count by indication, Poland, 2020–22

Figure 78: Pharmaceutical clinical trials count by phase, Poland, 2020–22

Figure 79: Top five pharmaceutical clinical trials sponsors by count, Poland, 2020–22

Figure 80: Medical devices clinical trials count by therapeutic areas, Poland, 2020–22al devices clinical trials count by trial status, Poland, 2020–22

Figure 81: Medical devices clinical trials count by indication, Poland, 2020–22

Figure 82: Medical devices clinical trials count by indication, Poland, 2020–22

Figure 83: Top five medical devices clinical trials sponsors by count, Poland, 2020–22

Figure 84: Strategic objectives of national medicines policy, Poland, 2018-22

Figure 85: Number of hospitals, Poland, 2013–21

Figure 86: Number of diagnostic equipment, Poland, 2012–19

Figure 87: Acute care hospital beds (per 1,000 population), Poland, 2013–21

Figure 88: Total number of hospital beds (per 1,000 population), Poland, 2013–21

Figure 89: Psychiatric care hospital beds (per 1,000 population), Poland, 2013–21

Figure 90: Immunization rate (%), Poland, 2013–21

Figure 91: Life expectancy at birth (years), Poland, 2013–20

Figure 92: CO2 emissions (million tons), Poland, 2013–21

Figure 93: PM2.5 (µg per m3), Poland, 2013–21

Figure 94: Physicians (per 1,000 population), Poland, 2013–21

Figure 95: Pharmacists per 1,000 population), Poland, 2013–21

Figure 96: Dentists (per 1,000 population), Poland, 2013–21

Figure 97: Nurses (per 1,000 population), Poland, 2013–21

Figure 98: Major causes of mortality (per 100,000 population), Poland, 2019

Figure 99: Major causes of male mortality (per 100,000 population), Poland, 2019

Figure 100: Major causes of female mortality (per 100,000 population), Poland, 2019

Figure 101: DALYs by major disease (per 100,000 population), Poland, 2019

Figure 102: Healthcare expenditure as percentage of GDP (%), Poland, 2013–21

Figure 103: Health expenditure share (% of total health spending), Poland, 2013–21

Figure 104: Pharmaceutical spending (% of total health spending), Poland, 2013–19

Figure 105: Healthcare expenditure components by function (% of total health expenditure), Poland, 2019

Frequently asked questions

Poland Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape thematic reports
Currency USD
$1,995

Can be used by individual purchaser only

$3,990

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Poland Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Poland Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape in real time.

  • Access a live Poland Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.